Enlivex Therapeutics, Ltd. (ENLV): Broker Consensus Forecast
The development of Enlivex Therapeutics (ENLV) is constrained by strict regulatory oversight and the complexity of biosynthesis, with the indicator standing at 1284.67. This price chart reflects market expectations for the Allocetra platform, which reprograms macrophages to combat sepsis and oncology. Business efficiency relies on a streamlined express delivery system for live cells between medical centers and laboratories, eliminating any transportation failures.
Analytical breakdowns for Enlivex Therapeutics (ENLV)
- current quotes and average value forecast:
- stock exchange capitalization data:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Enlivex Therapeutics|ENLV - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital enlivex.com|ENLV - Company Aggregate Debts|Debts to Book Capitalization Enlivex Therapeutics, Ltd.|ENLV - Company Long-Term Debt|Company Short-Term Loans and Borrowings Enlivex Therapeutics|Quick Liquidity Indicator enlivex.com
- financial results and valuation multiples details:
ENLV - Net Profit|Projected Future Earnings Enlivex Therapeutics|ENLV - Price to Earnings Ratio|Future Price to Earnings Multiple enlivex.com|ENLV - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Enlivex Therapeutics, Ltd.|ENLV - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Enlivex Therapeutics|ENLV - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months enlivex.com|ENLV - Net earnings per share growth this year|Earnings growth forecast for next year Enlivex Therapeutics
General company analysis:ENLV Enlivex Therapeutics Ltd
Amidst the fierce battle for patents in the field of macrophage immunotherapy, it is critically important to track market expectations regarding the value of Enlivex Therapeutics (ENLV) developments. The weighted consensus target for the stock aggregates the average fair value from various investment bank estimates, identifying unfounded optimism and reflecting the resilience of cash flows, which allows for an objective assessment of the company's capitalization against competitive threats.
Competitors of Enlivex Therapeutics
ARGX - Average Forecast Price|Price Target Chart BioNTech BNTX|ABVX: Broker Consensus Forecast|ADMA - Price Target Chart|PTGX: Price Target Chart|IMVT (Immunovant, Inc.) - Consensus Target|KNSA (kiniksa.com) - Price Target Chart|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|Average Forecast Price Aclaris Therapeutics, Inc|Kyverna Therapeutics (KYTX) - Price Target Chart|Broker Consensus Forecast TLSA|Price Target Chart Cabaletta Bio|Price Target Chart VTYX|Analyst Consensus Forecast THTX|Analyst Median Target Avalo Therapeutics Inc|Eledon Pharmaceuticals - Consensus Target|agenusbio.com - Price Target Chart|Climb Bio - Analyst Consensus Forecast|Average Forecast Price zurabio.com|ATYR (aTyr) - Consensus Target|Broker Consensus Forecast ADAG|Consensus Target IMA|STTK: Fair Value Consensus|Consensus Target EQ (Equillium, Inc.)|Analyst Forecast Prices CNTB|Analyst Consensus Forecast IMUX (Immunic)|Fair Value Consensus ATRA|InflaRx GmbH - Analyst Consensus Forecast|Average Forecast Price x4pharma.com|adicetbio.com (ACET) - Price Target Chart|Celularity - Fair Value Consensus|INMB (INmune Bio Corp) - Analyst Consensus Forecast|Analyst Consensus Forecast Barinthus Biotherapeutics Corp|Price Target Chart Kezar Life Sciences (KZR)|SABS: Forecast Levels Chart|Analyst Consensus Forecast AKTX (Akari Therapeutics Plc)|Q32 Bio Inc (QTTB) - Average Forecast Price|GOVX: Consensus Target|EDSA - Analyst Consensus Forecast|IBIO (iBio, Inc.) - Consensus Target|CARM: Analyst Forecast Prices|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Bolt Bio (BOLT) - Analyst Median Target|Analyst Consensus Forecast HCWB|Consensus Target aptevotherapeutics.com APVO|Price Target Chart AIM ImmunoTech AIM|Analyst Median Target Aditxt Inc. (ADTX)|GRI Bio - Analyst Consensus Forecast|Average Forecast Price XORTX Therapeutics Inc|ReShape Lifesciences (HIND) - Price Target Chart|Broker Consensus Forecast REVB|Price Target Chart Indaptus Therapeutics|Price Target Chart SCNI|Consensus Target CALI (CalciMedica, Inc.)|Price Target Chart AFMD (affimed.com)|Price Target Chart Allakos ALLK|HOOK (HOOKIPA Pharma, Inc.) - Forecast Levels Chart|IGM Bio - Analyst Consensus Forecast|Fair Value Consensus ITOS (iteostherapeutics.com)|OCEA: Analyst Consensus Forecast|TC BioPharm (Holdings) Plc (TCBP) - Analyst Consensus Forecast|Price Target Chart Third Harmonic Bio, Inc
